Comparison of the upper gastrointestinal safety of arthrotec® 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers

Agrawal, Naurang M.; Caldwell, Jacques R.; Kivitz, Alan; Weaver, Arthur L.; Bocanegra, Tomás S.; Ball, Julie; Dhadda, Shobha; Hurley, Steven; Hancock, Larry

doi:10.1016/s0149-2918(00)88318-6

Cited by 34 publications

(19 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mean duration of arthritis was reported in one study only 145 as being 10-11 years. Mean ages ranged from 62 years to 75 years.…”

Section: Participantsmentioning

confidence: 87%

“…The studies varied in size from at least 53 78 to 395 participants per arm. 145 The studies were performed in North and South America and China. Publication dates were from 1993 to 2001.…”

Section: Characteristics Of Studiesmentioning

confidence: 99%

“…146 The other study 145 did not state its funding, but five of nine authors appeared to be employed by Searle.…”

Section: Chapter 18mentioning

confidence: 99%

“…Further differences in data analysis between the two reviews should also be noted: one of the two studies 145 that compared a Cox-1 NSAID plus misoprostol with a Cox-2 preferential was excluded in the review by Rostom and colleagues. Another short-term study 67 included in this review was not found in the search by Rostom and colleagues.…”

Section: Comparisons With Other Literaturementioning

confidence: 99%

See 3 more Smart Citations

A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling

Brown¹,

Hooper²,

Elliott³

et al. 2006

Health Technol Assess

137

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta Medica/EMBASE and Science Citation Index Expanded (SciSearch ® ) and Current Contents® /Clinical Medicine. NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of car...

show abstract

“…Mean duration of arthritis was reported in one study only 145 as being 10-11 years. Mean ages ranged from 62 years to 75 years.…”

Section: Participantsmentioning

confidence: 87%

“…The studies varied in size from at least 53 78 to 395 participants per arm. 145 The studies were performed in North and South America and China. Publication dates were from 1993 to 2001.…”

Section: Characteristics Of Studiesmentioning

confidence: 99%

“…146 The other study 145 did not state its funding, but five of nine authors appeared to be employed by Searle.…”

Section: Chapter 18mentioning

confidence: 99%

Section: Comparisons With Other Literaturementioning

confidence: 99%

See 2 more Smart Citations

A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling

Brown¹,

Hooper²,

Elliott³

et al. 2006

Health Technol Assess

137

View full text Add to dashboard Cite

show abstract

“…More recent endoscopic studies have shown, that etodolac, nabumetone and meloxicam, which all have some COX-2 selectivity cause significantly less mucosal injury and peptic ulcer bleeding than the older NSAIDs including ibuprofen [28,[102][103][104][105][106][107][108][109]. As discussed by Laine, many of these studies are limited by the small numbers of patients and the short follow up period (most commonly 1-4 weeks) [5].…”

Section: Incidence Of Ulcers With Regular Nsaid Usementioning

confidence: 99%

Impact of COX-2 Inhibitors in Common Clinical Practice a Gastroenterologists Perspective

Lehmann

Beglinger

2005

CTMC

View full text Add to dashboard Cite

Non-selective NSAIDs enhance the risk of serious ulcer complications (bleeding, perforation, obstruction), hospitalization and death about 3-10-fold. The gastrointestinal side effects of NSAIDs have a considerable economical burden, since they are responsible for 5-10 billion dollars in hospitalization charges and lost work time. NSAIDs cause gastrointestinal damage by both topical and systemic effects. COX-1-mediated inhibition of prostaglandin synthesis is probably the most relevant mechanism, but NSAIDs can cause gastrointestinal injury also by COX-independent pathways. COX-2-selective inhibitors (Coxibs) such as celecoxib, rofecoxib or valdecoxib have been developed to achieve an equal relief of pain and inflammation as classical NSAIDs but without their risk of gastrointestinal side effects. Within the first three months, celecoxib became the fastest selling drug in history. The gastrointestinal safety of classical NSAIDs and Coxibs has been compared in a variety of endoscopic investigations, meta-analyses and outcome studies. In conclusion, these studies have clearly shown, that Coxibs are associated with significantly less dyspeptic symptoms, erosions, ulcers and ulcer complications. In contrast, Coxibs seem to delay gastric ulcer healing to the same extent as traditional NSAIDs. Besides their effects on the upper gastrointestinal tract, NSAIDs can cause small intestinal inflammation, ulcers of the small and large intestine, ileal dysfunction, intestinal strictures, colitis and NSAID enteropathy. In addition, NSAIDs increase the risk of lower gastrointestinal complications including bleeding, perforation and obstruction. Current data suggest, that Coxibs are associated with a significantly lower risk of serious lower GI events than traditional NSAIDs. It is now under debate, who should receive COX-2-selective inhibitors instead of classical NSAIDs, since Coxibs are much more expensive. Data from cost-effectiveness studies suggest, that Coxibs should currently be used only in patients with high risks of GI complications.

show abstract

Cyclooxygenase 2 Selective Agents and Upper Gastrointestinal Disease

Fernandez¹

2000

JAMA

View full text Add to dashboard Cite

Comparison of the upper gastrointestinal safety of arthrotec® 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers

Cited by 34 publications

References 30 publications

A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling

A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling

Impact of COX-2 Inhibitors in Common Clinical Practice a Gastroenterologists Perspective

Cyclooxygenase 2 Selective Agents and Upper Gastrointestinal Disease

Contact Info

Product

Resources

About